Company intelligence / Profile preview

Novacea

South San Francisco, California, United Statesreuters.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 3

Overview

Novacea developed two main oncology drug candidates. Asentar™ was a combination of docetaxel and high-dose calcitriol for androgen-independent prostate cancer; its pivotal ASCENT–2 Phase 3 trial was terminated early due to safety concerns. AQ4N (banoxantrone), a hypoxia-targeted prodrug/topoisomerase II inhibitor for solid tumors and hematological malignancies, reached Phase 1b/2a clinical trials in glioblastoma multiforme before development was scaled back. No ongoing clinical trials remain as of the company's acquisition by Transcept Pharmaceuticals.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

DN-101

Phase 3

Indications: Prostate cancer

Partnerships

Schering-Plough CorporationKuDOS/AstraZeneca

Beyond the preview

Go deeper on Novacea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novacea.

Explore the full profile